Despite facing a challenging market environment,
The Clorox Company (CLX) continues to attract investor attention, recently declaring a
regular quarterly dividend of $1.24 per share. However, analysts have mixed opinions, with some issuing a “Reduce” consensus rating while others, including
Jim Cramer, see it as a valuable investment. This dichotomy may be due to large stake sales by contributors such as Robeco Institutional Asset Management and Boston Trust Walden Corp, contrasted against new investment activity from companies like Stance Capital and Hudson Bay Capital Management.
Price target adjustments have also been common, with both
Goldman Sachs and Wells Fargo lowering targets. Notably, CLX's earnings have beat estimates, inciting price valuation discussions and shareholder voting announcements. Looking ahead, Clorox's projected financial performance and recovery efforts, along with a probable
undervaluation of 47%, make the company an interesting target for investors. Attention has also been drawn to Clorox’s
5% yield and potential for cost reset and health-focused initiatives to change investment narratives. Despite potential volatility and soft Q1 performance, a consensus remains
defensive approach and dividend strength make CLX a relatively safe bet.
Clorox Company CLX News Analytics from Sat, 01 Mar 2025 08:00:00 GMT to Fri, 09 Jan 2026 11:58:23 GMT -
Rating 2
- Innovation 3
- Information 7
- Rumor -4
